Galapagos selects pre-clinical candidate drug for cachexia
Galapagos' pre-clinical candidate G100192 binds very selectively and strongly to targeted androgen receptors, potentially enabling the candidate drug to be efficacious without cardiovascular, prostate, or virility side effects traditionally seen in androgen therapies. Galapagos aims for once-a-day oral dosing that improves muscle mass and function, with minimal effects on hormonal status of cachexia patients. Animal studies completed thus far encourage the Company to continue toward this goal.
In its SARM program, Galapagos' strategy has been to pursue a first indication in cachexia, with possible second indication in osteoporosis. In February 2008, Galapagos announced that the SARM lead compound had limited bioavailability. Thereafter, its research group at the Biocitech Park in Romainville obtained a breakthrough in potency and oral bioavailability, leading to a pre-clinical candidate within 10 months.
G100192 is a novel compound for which patents are pending, providing freedom to operate. This program is an addition to the Company's portfolio of unpartnered R&D programs that address known drug targets, which also includes an integrin receptor antagonist (IRA) program in bone metastasis and Nanocort©, a liposome formulation of prednisolone for acute flares in rheumatoid arthritis and multiple sclerosis.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.